The Use of Recombinant Cholera Toxin-B for the Treatment of Inflammatory Bowel Disease
Posted Jul 15 2010 5:00pm
Description of Invention: The present invention provides methods of treating inflammatory bowel disease in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B (CT-B). In particular, the present invention provides methods of decreasing the activity of interferon-gamma in a subject, decreasing the activity of IL-12 in a subject, and treating or preventing a Th1 T-cell mediated autoimmune disorder.
Inventors: Warren Strober (NIAID) Monica Boirivant (NIAID) Ivan J Fuss (NIAID) Brian L Kelsall (NIAID)
Portfolios: Internal Medicine - Therapeutics Rare Diseases
For Additional Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220